Summary & Overview
CPT 81448: Hereditary Peripheral Neuropathy Genomic Sequence Analysis Panel
CPT code 81448 represents a genomic sequence analysis panel for hereditary peripheral neuropathies, including conditions such as Charcot-Marie-Tooth disease and spastic paraplegia. This code is significant nationally as it supports advanced molecular diagnostics by requiring sequencing of at least five relevant genes, facilitating precise identification of genetic causes for peripheral neuropathies. The procedure is classified under Genomic Sequencing Procedures and Other Molecular Multianalyte Assays and is typically performed in laboratory settings.
Major payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication provides insights into payer coverage, clinical context, and policy benchmarks for this code. Readers will learn about the clinical applications of 81448, payer policies, and relevant billing practices, including common modifiers and associated taxonomies. The summary also highlights related CPT codes and ICD-10 diagnoses that may be encountered in the context of hereditary neuropathy testing.
This article is designed to inform healthcare professionals, laboratory administrators, and policy analysts about the current landscape for 81448, including payer coverage and clinical relevance. It offers a comprehensive overview of the code’s role in genetic testing for peripheral neuropathies, supporting informed decision-making in laboratory medicine and molecular pathology.
CPT Code Overview
CPT code 81448 is used for genomic sequence analysis panels targeting hereditary peripheral neuropathies, such as Charcot-Marie-Tooth disease and spastic paraplegia. This procedure involves sequencing at least five genes associated with peripheral neuropathy, including BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, and SPTLC1. The service type is Genomic Sequencing Procedures and Other Molecular Multianalyte Assays, and it is typically performed in a laboratory setting (Place of Service 81). This code enables comprehensive genetic testing to support diagnosis and management of inherited neuropathic conditions.
Clinical & Coding Specifications
Clinical Context
A patient presents with symptoms suggestive of hereditary peripheral neuropathy, such as progressive muscle weakness, sensory loss, or gait disturbances. The clinician suspects a genetic etiology, such as Charcot-Marie-Tooth disease or hereditary spastic paraplegia. After clinical evaluation and family history assessment, the provider orders a genomic sequence analysis panel to identify mutations in at least five peripheral neuropathy-related genes (e.g., BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1). The specimen is sent to a laboratory (Place of Service 81) specializing in molecular genetic pathology. Results inform diagnosis, prognosis, and potential management strategies for the patient and family.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component of the laboratory service, such as interpretation of results by a pathologist. - Modifier
TC: Used when reporting only the technical component, which includes specimen processing and sequencing.
- Modifier
-
Provider Taxonomies:
Code Specialty Name 207ZP0102XPathology - Clinical Pathology/Laboratory Medicine 207ZP0105XPathology - Molecular Genetic Pathology 207L00000XAnatomic Pathology
These taxonomies represent providers specializing in laboratory medicine, molecular genetic pathology, and anatomic pathology, who are qualified to perform and interpret genomic sequencing procedures.
Related Diagnoses
-
C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung- This code may be used if a patient with hereditary neuropathy also has a history of lung cancer, though it is not directly related to the primary indication for the genomic panel.
-
C50.919: Malignant neoplasm of unspecified site of unspecified female breast- Relevant if the patient has a concurrent or past diagnosis of breast cancer, but not directly tied to hereditary neuropathy testing.
-
C18.9: Malignant neoplasm of colon, unspecified- Used if the patient has colon cancer; may be included for patients with complex medical histories.
-
C61: Malignant neoplasm of prostate- Indicates prostate cancer; not directly related to hereditary neuropathy but may be present in the patient's history.
-
C25.9: Malignant neoplasm of pancreas, unspecified- Used for patients with pancreatic cancer; not directly relevant to the neuropathy panel but may be coded for comorbidities.
These ICD-10 codes represent malignancies that may be present in patients undergoing genomic testing, but are not primary indications for the hereditary peripheral neuropathies panel. The panel is primarily indicated for suspected inherited neuropathies.
Related CPT Codes
81439: Inherited cardiomyopathy (e.g., hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYBPC3, MYH7, PKP2, and TTN.
81439 is related to 81448 as both are genomic sequence analysis panels targeting inherited conditions. While 81448 focuses on hereditary peripheral neuropathies, 81439 addresses inherited cardiomyopathies. These codes may be used together in cases where a patient has overlapping clinical features or family history of both neuropathies and cardiomyopathies, but are generally alternatives based on the suspected genetic disorder.
National Reimbursement Benchmarks
National mean rates for CPT 81448 show that BUCA (average commercial) payers reimburse at $505.83, while Medicare rates are not available in the input. Among individual commercial payers, Cigna has the highest mean rate at $555.96, and Aetna the lowest at $477.99.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. UnitedHealth Group exhibits the widest spread ($298.50), followed by Cigna ($422.75), indicating substantial variability in contracted rates. Aetna has the tightest range ($169.50), suggesting more consistent reimbursement levels. Blue Cross Blue Shield and BUCA also show moderate dispersion.
The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.